Let me guess the next 6 months. Capital raising at higher SP for pipeline expansion and market penetration followed by shorting/pushing it back down to 30 cents.
Having said this, the tech and management plan seem good. Like all other Australian small biotech companies, how does one predict profitablity?
Ann: Becoming a substantial holder, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
0.040(6.61%) |
Mkt cap ! $146.3M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 66.5¢ | 61.0¢ | $128.3K | 200.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 1515 | 1 |
View Market Depth
| Last trade - 15.52pm 15/10/2024 (20 minute delay) ? |
| GSS (ASX) Chart |